Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England.
Shakir
S A
SA
Drug Safety Research Unit, Bursledon Hall, Southampton SO31 1AA. saad.shakir@dsru.org
Wilton
L V
LV
Boshier
A
A
Layton
D
D
Heeley
E
E
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D002423:Cause of Death; D011307:Drug Prescriptions; D004739:England / Q000453:epidemiology; D007172:Erectile Dysfunction / Q000188:drug therapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D015996:Survival Rate
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases